|
As we approach the threshold of a new year, it offers a natural moment to pause and reflect—on the achievements of the past year, the lessons learned, and the opportunities yet to be fulfilled. However, this time can also be an opportunity for collective vision-building, where individuals, groups, and collective entities with shared intentions for growth, unity, and transformation. A renewed vision for the coming year is not just about setting goals, but also about fostering collective progress, responsibility, and hope.
Honoring the Legacy of Dr. Loyd V. Allen
2024 has indeed been an eventful year, one marked by both loss and growth. This year began with the passing of our founder, Dr. Loyd V. Allen. As we continued to be saddened by his loss, we celebrate his profound contributions to the International Journal of Pharmaceutical Compounding (IJPC) and to the broader pharmaceutical sciences industry. At IJPC, we are dedicated to honoring Dr. Allen's remarkable legacy by continuing to expand the Journal's influence and reach within the field of pharmaceutical compounding. His vision and leadership continue to inspire our work as we strive to advance the science and practice of compounding, supporting professionals and making a lasting impact on the industry.
Reflecting on 2024
We are especially proud to have established the USP Loyd Allen Education Grant and Fellowship Award. We are excited to announce that USP will begin accepting applications for its first recipient in 2025. This award aims to enhance and advocate for quality education for pharmacy professionals in compounding, in alignment with Dr. Allen's mission.
As the year drew to a close, IJPC also held a strategic planning meeting to review our achievements and set goals for 2025. This meeting emphasized the importance of creating a collective vision for the coming year, transforming our intentions into actionable plans.
Compounding Regulatory Updates
We prioritize providing you with essential resources to stay informed and up to date on trending topics in the world of compounding. Below are highlights that might be beneficial.
- Best Practices When Compounding FDA-Approved Drugs in Shortage: This Alliance for Pharmacy Compounding (APC) guidance focuses on ensuring the safety of patients when compounding medications that are FDA-approved but in shortage. It outlines proper procedures and protocols to maintain quality and prevent potential risks when pharmacists are tasked with filling the gap caused by drug shortages.
- Best Practices for Marketing Compounded Medications: This APC release provides insight into the best practices for marketing compounded medications, specifically aiming to help pharmacists navigate the legal risks associated with promoting these products. It emphasizes adhering to regulations and ensuring that marketing practices comply with legal standards to avoid potential lawsuits.
- Compounded GLP-1 Drugs and Patient Adverse Events: The APC issued a brief addressing comments made by the CEO of Novo Nordisk regarding adverse events linked to compounded semaglutide. This brief helped clarify misconceptions surrounding the safety of compounded versions of this drug and offered transparency on the subject.
- FDA Tirzepatide Shortage Announcement: In mid-December, the FDA announced the tirzepatide shortage officially over. This milestone means that compounding of tirzepatide by 503A and 503B compounding sites will cease in the coming months.
- NIOSH Hazardous Drugs List Update: The National Institute for Occupational Safety and Health (NIOSH) released an updated list of hazardous drugs in healthcare settings in December. This update added 25 new drugs, 12 of which have special handling requirements as outlined by the manufacturers. Seven drugs were removed, reflecting shifts in their safety profiles or handling requirements.
Looking Ahead to 2025
The start of a new year provides an ideal opportunity to establish a collective vision, a unified sense of purpose that transcends individual pursuits. As we look ahead to 2025, IJPC enters the new year with renewed spirit and energy. Our goals are focused on ensuring long-term sustainability and scalability, as we believe that every challenge brings with it a wealth of opportunity.
At IJPC, we are enthusiastic about making progress, expanding our network, and incorporating more compounding entities to foster growth. Our commitment to maintaining a solid foundation of experienced compounding pharmacists remains unwavering, while we also strive to build and support the emerging generations of compounding professionals. By nurturing the next generation of leaders, we are paving the way for IJPC to become a truly international journal for pharmaceutical compounding, ensuring that we stay relevant and influential for years to come.
With this vision, we are confident that IJPC will continue to thrive and make a significant impact on the compounding community, now and in the future.
Help Us Serve You Better - Share Your Insights!
At IJPC, our vision is to build meaningful connections within the compounding community, and we want to ensure that we are meeting your needs. Your input is vital to help us create the content and resources that will fuel your growth and success.
We would love to hear from you! Please take a few minutes to complete this brief survey and help us serve you better. Thank you for your time and valuable feedback!
Respectfully,
|
